Recent news on Leuprolide Acetate

Psychiatric Sequelae of Traumatic Brain Injury: A Case Report  -  May 2, 2007
Am J Psychiatry (subscription)There is a significant literature on the use of medroxyprogesterone and leuprolide acetate for the treatment of paraphilias and hypersexual behavior in

First six-month cancer dosage introduced to Europe  -  Mar 1, 2007
In-PharmaTechnologist.com,01/03/2007 - MediGene's six-month dosage of its prostate cancer drug Eligard (leuprolide acetate) is now available in Germany, the company announced today.

Takeda and TAP to Promote Sucampo's AMITIZA(R) in the United States  -  Feb 26, 2007
PR Newswire (press release),TAP markets Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more information about TAP Pharmaceutical Products

Cash infusion could revive work on Alzheimer's drug  -  Jan 27, 2007
News & Observer,Memryte, which is implanted under the skin, consists of a small, biodegradable tube filled with leuprolide acetate, an experimental booster of approved

People magazine: Don't stop, get a shot  -  Jan 30, 2007
WorldNetDaily,She can expect her body to be barraged with estrogen, progesterone, leuprolide acetate, follicle stimulating hormone, human menopausal gonadotropins and

Eligard(R) (leuprolide acetate) 6-Month Formulation Approved in ...  -  Dec 1, 2006
DG NewsThe Atrigel technology allows for sustained delivery of leuprolide acetate for periods ranging from one to 6 months. Eligard works by lowering the levels of

DURECT Provides an Update to the Memryte(TM) Program Under ...  Oct 24, 2006
Memryte utilizes DURECT's proprietary DURIN technology to provide sustained release of the peptide leuprolide acetate and is based on Voyager's patented method ... -Drug Newswire (press release), Voyager Pharmaceuticals’ Financial Plight Is A True Tragedy ...  Oct 20, 2006
Voyager touted the results at an international Alzheimer’s conference in July. "Women treated with leuprolide acetate and the current standard of care ... -Local Tech Wire, DURECT Says Voyager Closes Trial Of Alzheimer's Drug Memryte ...  Oct 19, 2006
Memryte utilizes DURECT's proprietary DURIN technology to provide sustained release of the peptide leuprolide acetate and is based on Voyager's patented method ... -Trading Markets, Estrogen Preserves Working Memory in Pre- but Not Postmenopausal ...  Oct 16, 2006
The second study was a prospective design and included 25 premenopausal women with an average age of 36 who received leuprolide acetate depot (LAD), a ... -Medscape (subscription) Increased Co-Payments For Expensive Specialty Drugs Won't Cut ...  Sep 13, 2006
For example 1,943 patients with prostate cancer spent $6.3 million for leuprolide acetate (Lupron), or about $3,200 a year per patient. ... -All American Patriots

Cougar Biotechnology Appoints Dr. Russell Ellison to Board of ...  Sep 11, 2006
...he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate for injectable ... -Genetic Engineering News

Eligard(R) (leuprolide acetate) 6-Month Formulation Approved in ...  -  Dec 1, 2006
DG NewsThe Atrigel technology allows for sustained delivery of leuprolide acetate for periods ranging from one to 6 months. Eligard works by lowering the levels of

Drop in estrogen impairs memory  Aug 23, 2006
Sherwin and her colleagues studied 25 women, ages 25 to 40, who were taking a drug called leuprolide acetate depot as part of treatment for benign ... -Macleans

Researchers Link Estrogen Levels, Memory Loss In Younger Women  Aug 23, 2006
In the course of their regular treatment, these women were given leuprolide acetate depot (Lupron), a drug that chemically suppresses ovarian function and ... -eMaxHealth.com

Applying brakes to symptoms of Alzheimer's with a tiny implant  Jul 26, 2006
Leuprolide acetate, the medicine which has been in use for over two decades to treat prostate cancer is now being used inside the implant and research has ... -MedIndia



Leuprolide Acetate Stabilizes Cognitive and Functional Decline in ...  16 May 2006
RALEIGH, NC, May 16 /PRNewswire/ -- Leuprolide acetate, when used in conjunction with standard Alzheimer's therapy, was shown to stabilize the cognitive and ... - Yahoo! News

(PRN) - Answers.com Releases 1-Click Answers 2.0 ... [+]  16 May 2006
...[+]. (PRN) - Leuprolide Acetate Stabilizes Cognitive and Functional Decline in Women With Alzheimer's Disease, Study Shows ... [+. ... - Bolsamania.com

Voyager Pharmaceutical Corporation Completes Second Phase II ...  May 3, 2006
Voyager Pharmaceutical Corporation announced Wednesday the completion of a Phase II study that assessed the safety and efficacy of leuprolide acetate in the ... - Yahoo! News

Voyager Pharmaceutical Corporation Completes Second Phase II ...  May 3, 2006
RALEIGH -- Voyager Pharmaceutical Corporation has completed a Phase II study that assessed the safety and efficacy of leuprolide acetate in the treatment of ... - Carolina Newswire

Lawsuit alleges co-founder derailed IPO  May 5, 2006
At the time, Bowen was a physician practicing in Naples, Fla., and the holder of a patent on leuprolide acetate as a possible treatment for Alzheimer's disease ... - News & Observer

Voyager Pharmaceutical Corporation to Present at the 9th ...  Apr 18, 2006
...information at Voyager Pharmaceutical Corporation, will discuss the stabilization of cognitive decline in AD following treatment with leuprolide acetate. ... - PR Newswire





Valera finishes early puberty study  11 Apr 2006
This market is dominated by Lupron Depot-PED (leuprolide acetate for depot suspension) produced by TAP Pharmaceutical Products, which involves intramuscular ... - Pharmaceutical Business Review

Enrollment Passes Midpoint in Voyager Pharmaceutical Corporation's ...  11 Apr 2006
Voyager's most advanced product candidate is VP4896, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, in ... - PR Newswire

Valera Pharmaceuticals Completes Phase III Study of Its Twelve ...  Apr 6, 2006
This market is dominated by Lupron Depot-PED(R) (leuprolide acetate for depot suspension) from TAP Pharmaceutical Products, Inc. ... - International News Service

Lupron rival could return to market in May  Apr 6, 2006
US District Judge James Zagel of Chicago outlined key similarities of the drugs, both sustained-release versions of the same drug known as leuprolide acetate. ... - Chicago Tribune

Children With GERD Can Go Undiagnosed for Months  Mar 22, 2006
Pharmaceutical Company Limited, of Osaka, Japan. TAP markets Prevacid and Lupron Depot® (leuprolide acetate for depot suspension). - EndoNurse

Dendreon Names Christopher Lockett Head of Government Affairs  Mar 23, 2006
...federal programs, including Medicare and Medicaid, as well as legislative issues on TAP's two leading products, Lupron Depot® (leuprolide acetate for depot ... - Yahoo! News

Children with Pediatric Gastroesophageal Reflux Disease (GERD) Can ...  Mar 22, 2006
Limited, of Osaka, Japan. TAP markets Prevacid and Lupron Depot(R) (leuprolide acetate for depot suspension). For more information ... - PharmaLive.com



New Formulation of Leuprolide Administered Every Six Months  Feb 21, 2006
A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer. ... - Cancer Consultants,

Depot Delivery System Maintains Steady Drug Level in Prostate ...  Feb 16, 2006
2006 (Reuters Health) - LA-2585 (Atrix Laboratories), an extended release subcutaneous formulation for the long-term delivery of leuprolide acetate, appears to ... - Cancerpage.com,

Rich Daly Joins TAP As Senior Marketing Executive  Feb 2, 2006
...marketing strategy and initiatives for TAP's current and future brands - including Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot ... - International News Service

Joseph DeVeaugh-Geiss, MD, Expands Role as Interim Chief Medical ...  Jan 16, 2006
...along with the Phase II and Phase III double-blind, placebo-controlled trials (ALADDIN) investigating the safety and effectiveness of leuprolide acetate as a ... - Biotech Intelligence

CMS Issues Final Rule on Competitive Acquisition of Medicare Part ...  Jan 20, 2006
Because all carriers have adopted LCA policies for injectable forms of leuprolide acetate, CMS has not included this product in the CAP. ... - Mondaq News Alerts

Voyager Pharmaceutical Names Interim Chief Medical Officer  Jan 16, 2006
DeVaugh-Geiss has been involved in all three phases of trials for Voyager’s drug leuprolide acetate, which is seen as a potential treatment for Alzheimer’s ... - Local Tech Wire

Preserving Competition, FTC Requires Divestitures Before Allowing ...  Jan 23, 2006
3) pergolide mesylate tablets from Teva, to be divested to Par; 4) estazolam tablets from IVAX, to be divested to Par; 5) leuprolide acetate injection kits ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional